Form D · Pharmaceuticals
Biolytx Pharmaceuticals Corp
Oklahoma City, OK · CIK 0001656890
Offering snapshot reported Oct 29, 2015 · SEC filing
- Reported sold
- $1.32M Offering amount: $1.42M
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Oct 16, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 29, 2015 | Initial | $1,317,971 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Debt, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-250274
The total amount sold includes $1,000,000 sold and funded at closing on 10-16-15, $100,000 sold and to be funded in Sept 2016, and $217,971 of preexisting outstanding indebtedness of the company cancelled and converted into the securities sold.
Source: Form D, filed Oct 29, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Douglas A Branch | Executive |
| William A Hagstrom | Director |
| H Anne Pereira | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
800 Research Parkway Suite 334
Oklahoma City, OK, 73104
Oklahoma City, OK, 73104